Pharma Faces: Shirley Xu, Baxter China
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology, as well as musculoskeletal system, alimentary tract and metabolism, blood and blood-forming organ, genito-urinary system and sex hormone, and other therapeutic areas.
It provides approximately 800 varieties of drugs and 20 dosage forms. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it operates a network of retail pharmacy stores, as well as engages in consulting service, assets management, investment holding operations, etc. Further, the company manufactures and trades in medicines, and medical equipment and instruments; and rents properties, as well as wholesales chemicals and active pharmaceutical ingredients. It operates approximately 1,892 chained pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People’s Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually…
Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs…
Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the…
The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang,…
Dr Dong Wei, CEO of EdiGene, shares the fascinating story behind the establishment of EdiGene, including his close relationship with EdiGene founder Professor Wensheng Wei; the insights he bring from…
Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio…
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
Michael Zhang, chairman of Peijia Medical, shares Peijia Medical’s mission to become a two-platform medical device company as well as the partner of choice for physicians in China and globally.…
PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews,…
Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to…
With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the…
See our Cookie Privacy Policy Here
